Tisotumab vedotin (TV) + pembrolizumab (pembro) in first-line (1L) recurrent or metastatic cervical cancer (r/mCC): Interim results of ENGOT Cx8/GOG 3024/innovaTV 205 Meeting Abstract
| Authors: | Lorusso, D.; Vergote, I.; O'Cearbhaill, R. E.; Westermann, A. M.; Banerjee, S. N.; Van Nieuwenhuysen, E.; Iglesias, D. A.; Collins, D. C.; Cibula, D.; Madsen, K.; Tewari, K. S.; Pignata, S.; Baurain, J. F.; Boere, I. A.; denys, H.; Andreassen, C. M.; Soumaoro, I.; Jain, S.; Gennigens, C. N.; Monk, B. J. |
| Abstract Title: | Tisotumab vedotin (TV) + pembrolizumab (pembro) in first-line (1L) recurrent or metastatic cervical cancer (r/mCC): Interim results of ENGOT Cx8/GOG 3024/innovaTV 205 |
| Meeting Title: | 2022 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 40 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2022 Jun 3-7 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2022-06-01 |
| Language: | English |
| ACCESSION: | WOS:000863680301559 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2022.40.16_suppl.5507 |
| Notes: | Meeting Abstract: 5507 -- Meeting also held virtually -- Source: Wos |
